Wendy Leng, MD
Urogynecology and Reconstructive Pelvic Surgery · Fort Worth, TXNPI 1891769022
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,161 of the $9,736 with a category attached, or 73.5%. 33 manufacturers reported payments, led by Medtronic at 45.2% of the total.
Across 310 payments — averaging $31.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Caldera Medical, Inc$923
- Astellas Pharma US Inc$749
- Sumitomo Pharma America, Inc.$559
- AbbVie$529
- Boston Scientific$462
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,34014%
- Grants$1141%
- Travel & lodging$94410%
- Food & beverage$7,16174%
- Education$991%
- Gifts$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 99 | $4,401 |
| Caldera Medical, Inc | 11 | $923 |
| Astellas Pharma US Inc | 43 | $749 |
| Sumitomo Pharma America, Inc. | 54 | $559 |
| AbbVie(2 entities) | 22 | $529 |
| Boston Scientific | 14 | $462 |
| Axonics, Inc. | 20 | $450 |
| Johnson & Johnson | 5 | $257 |
| Valencia Technologies Corporation | 4 | $178 |
| Olympus America Inc. | 7 | $178 |
| Urogen Pharma, Inc. | 2 | $144 |
| Coloplast | 1 | $137 |
| Innovation Technologies Inc | 1 | $109 |
| Ferring Pharmaceuticals Inc. | 1 | $98 |
| Sun Pharmaceutical Industries Inc. | 1 | $76 |
| Laborie Medical Technologies Corp. | 4 | $70 |
| Merck | 1 | $68 |
| Therapeuticsmd, Inc. | 3 | $48 |
| Bluewind Medical | 1 | $46 |
| Cook Medical LLC | 2 | $32 |
| Urovant Sciences Inc | 2 | $30 |
| Avation Medical, Inc. | 1 | $24 |
| Neotract Inc. | 1 | $19 |
| Blue Earth Diagnostics | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| TELA Bio, Inc. | 1 | $15 |
| 180 Medical, Inc. | 1 | $15 |
| Procept Biorobotics Corporation | 1 | $15 |
| Mission Pharmacal Company | 1 | $15 |
| Accord Healthcare, Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,205
- Desara$700
- Vertessa$700
- JELMYTO$119
- Erleada$117
- AKEEGA$117
- Lupron Depot$114
- Irrisept$109
- eCoin Device Kit$102
How this compares
$9,736 in reported general payments places this provider in the 70th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 108 | $88,441 |
| MyrbetriqMirabegron | 67 | $41,973 |
| Methenamine Hippurate | 350 | $24,953 |
| Estradiol | 95 | $5,924 |
| NitrofurantoinNitrofurantoin Macrocrystal | 71 | $2,254 |
| Oxybutynin Chloride ErOxybutynin Chloride | 66 | $1,571 |
| Solifenacin Succinate | 20 | $803 |
| Tamsulosin Hcl | 39 | $543 |
| Tramadol Hcl | 89 | $245 |
| Cephalexin | 52 | $182 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $559 | $88,441108 claims |
| Astellas Pharma US IncMyrbetriq | $749 | $41,97367 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Fort Worth
- Christopher RipperdaFort Worth$4K
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Tracy Cannon-SmithArlington$29K
- Teresa IrwinSan Marcos$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.